Cumberland Pharmaceuticals Inc.
CPIX
$2.86
$0.062.14%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 10.56% | 14.97% | 13.97% | 8.06% | -2.60% |
| Total Other Revenue | 210.12% | -34.76% | -34.76% | -34.76% | -34.76% |
| Total Revenue | 17.57% | 12.21% | 11.34% | 5.81% | -4.26% |
| Cost of Revenue | 1.23% | 4.28% | 2.35% | 0.69% | 8.56% |
| Gross Profit | 21.01% | 13.80% | 13.24% | 6.82% | -6.58% |
| SG&A Expenses | 10.28% | -1.57% | -1.38% | -1.83% | -3.28% |
| Depreciation & Amortization | -15.03% | -0.08% | -0.69% | 0.08% | -0.22% |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 6.80% | 0.75% | -0.70% | -2.25% | -3.20% |
| Operating Income | 56.59% | 56.06% | 60.62% | 50.05% | -3.57% |
| Income Before Tax | 56.32% | 68.68% | 71.31% | 60.25% | -2.88% |
| Income Tax Expenses | 276.75% | -167.40% | -162.52% | -156.77% | -149.89% |
| Earnings from Continuing Operations | 55.54% | 69.22% | 71.79% | 60.82% | -1.78% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | 179.50% | 136.12% | -11.32% | 234.96% | -170.23% |
| Net Income | 56.23% | 69.38% | 71.75% | 61.08% | -3.19% |
| EBIT | 56.59% | 56.06% | 60.62% | 50.05% | -3.57% |
| EBITDA | 188.45% | 147.98% | 159.61% | 188.06% | -20.00% |
| EPS Basic | 58.91% | 69.92% | 71.13% | 59.86% | -3.90% |
| Normalized Basic EPS | 61.42% | 57.23% | 55.30% | 32.38% | -112.21% |
| EPS Diluted | 58.66% | 69.01% | 70.19% | 58.21% | -4.79% |
| Normalized Diluted EPS | 61.06% | 56.90% | 54.96% | 32.03% | -111.31% |
| Average Basic Shares Outstanding | 6.36% | 4.25% | 2.24% | 0.27% | -1.67% |
| Average Diluted Shares Outstanding | 6.93% | 4.81% | 2.80% | 0.54% | -2.33% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |